

AGENCY RESOURCES FOR CORONAVIRUS RESPONSE

Keeping Workers Employed

- Small Business Administration – Coronavirus Small Business [Guidance](#) and Loan Resources
 - Paycheck Protection [Program](#)
 - COVID-19 Economic Injury Disaster Loan [Application](#)
- Treasury Department – [Resources](#) for the Paycheck Protection Program
 - [Overview](#) of the Program
 - [Information](#) and [Application](#) for Lenders
 - [Information](#) and [Application](#) for Borrowers
- Treasury Department – [FAQ](#): Employee Retention Credit
- Small Business Administration – Interim Final [Rule](#) Business Loan Program Temporary Changes; Paycheck Protection Program

Families and Workers

- Department of Labor – [Resources](#) for COVID-19 and the American Workplace
 - Families First Coronavirus Response Act: Employee Paid Leave [Rights](#)
 - Families First Coronavirus Response Act: Employer Paid Leave [Requirements](#)
 - Families First Coronavirus Response Act: [Questions and Answers](#)
 - COVID-19 and the Fair Labor Standards Act: [Questions and Answers](#)
 - COVID-19 and the Family and Medical Leave Act: [Questions and Answers](#)
- Department of Labor – Temporary [Rule](#) on Paid Leave under the Families First Coronavirus Response Act and [Summary](#)
- Department of Labor – [Guidance](#) on Temporary Emergency State Staffing Flexibility and Summary of CARES Act Unemployment Insurance Provisions
- Department of Labor – Unemployment Insurance [Relief](#) During COVID-19 Outbreak



- Department of Treasury – Social Security Recipients Will Automatically Receive Economic Impact [Payments](#)
- IRS – Main [Page](#) for Coronavirus Tax Relief Information
- IRS – Economic Impact Payments (Recovery Rebates): What You [Need](#) to Know
- IRS – [Warning](#) about Scams on the Economic Impact Payments (Recovery Rebates)
- IRS – [FAQ](#) on COVID-19 Related Tax Credits for Required Paid Sick Leave and Paid Family Leave, under the Families First Coronavirus Response Act
- IRS – [Notice](#) on Paid Qualified Sick Leave Wages and Family Leave Wages
- IRS – [FAQ](#) on the Employee Retention Credit in the CARES Act
- IRS – [Notice](#) on Relief from Penalty for Failure to Deposit Employment Taxes
- IRS – [Notice](#) on Relief for Taxpayers Affected by Ongoing Coronavirus Disease 2019 Pandemic, Related to Gift and Generation-Skipping Transfer Tax Filing and Payment Deadlines
- Department of Education – Coronavirus and Forbearance [Information](#) for Students, Borrowers, and Parents

Economic Stabilization for Distressed Industries

- Treasury Department – [Guidelines](#) and Application Procedures for Payroll Support to Air Carriers and Contractors
- Treasury Department – [Procedures](#) and Minimum Requirements for Loans to Air Carriers and Eligible Businesses and National Security Businesses
- Treasury Department – [Guidelines](#) and Application Procedures for Payroll Support to Air Carriers and Contractors

Health Care

- Centers for Disease Control and Prevention – [FAQ](#) on Infection Control
- Centers for Disease Control and Prevention – [FAQ](#) for Healthcare Professionals
- Centers for Disease Control and Prevention – [FAQ](#) on Personal Protective Equipment
- Centers for Disease Control and Prevention – [Information](#) for Health Departments on Reporting Cases of COVID-19



- Centers for Medicare and Medicaid Services – Main [Page](#) for Coronavirus Emergency Response
- Centers for Medicare and Medicaid Services – COVID-19 Emergency Declaration Health Care Providers [Fact Sheet](#)
- Centers for Medicare and Medicaid Services – [FAQ](#) on Medicare Telehealth
- Centers for Medicare and Medicaid Services – Long-Term Care Nursing Homes Telehealth and Telemedicine [Toolkit](#)
- Centers for Medicare and Medicaid Services – [FAQ](#) on Coverage and Payment Related to COVID-19
- Centers for Medicare and Medicaid Services – Expansion of the Accelerated and Advanced Payments Program in the CARES Act [Fact Sheet](#)
- Centers for Medicare and Medicaid Services – [FAQ](#) for State Medicaid and Children’s Health Insurance Program Agencies
- Centers for Medicare and Medicaid Services – Medicaid and CHIP COVID-19 Response [Toolkit](#)
- Centers for Medicare and Medicaid Services – Medicaid Telehealth Services [Fact Sheet](#)
- Centers for Medicare and Medicaid Services – [FAQ](#) on the Availability and Usage of Telehealth Services through Private Health Insurance Coverage
- Centers for Medicare and Medicaid Services – [Waivers](#) and Flexibilities
- Centers for Medicare and Medicaid Services – [Guidance](#) on Payment and Grace Period Flexibilities for Issuers Offering Coverage on the Federally Facilitated Exchanges and State-Based Exchanges on the Federal Platform
- Centers for Medicare and Medicaid Services – [FAQ](#) on Prescription Drugs and COVID-19 for Issuers Offering Health Insurance Coverage in the Individual and Small Group Markets
- Centers for Medicare and Medicaid Services – Guidance Regarding Enhanced Medicaid Funding for States – Federal Medical Assistance Percentage [FAQ](#)
- Centers for Medicare and Medicaid Services – End Stage Renal Disease Facilities: CMS Flexibilities to Fight COVID-19 [Fact Sheet](#)
- Drug Enforcement Administration – Registrant [Guidance](#) on Controlled Substance Prescription Refills
- Drug Enforcement Administration – [Exception](#) to Separate Registration Requirements Across State Lines



- Drug Enforcement Administration – [Exception](#) to Regulations Emergency Oral CII Prescription
- Drug Enforcement Administration – [Use](#) of Mobile Devices in Issuance of Electronic Prescribing of Controlled Substances
- Drug Enforcement Administration – [Exemption](#) Allowing Alternate Delivery Methods for Opioid Treatment Programs
- Drug Enforcement Administration – DEA [Guidance](#): Methadone Shortages
- Federal Emergency Management Agency – [Fact Sheet](#) on the Supply Chain Stabilization Task Force
- Food and Drug Administration – Coronavirus Treatment Acceleration Program [Resources](#)
- Food and Drug Administration – [Information](#) Regarding Drug Shortages of Hydroxychloroquine and Chloroquine
- Health Resources and Services Administration – COVID-19 [FAQs](#) for Grantees
- Health Resources and Services Administration – COVID-19 [Resources](#) for 340B Program Participants
- Health Resources and Services Administration – COVID-19 [FAQs](#) for Rural Health Programs
- Health Resources and Services Administration – COVID-19 [FAQs](#) for Health Centers
- Health Resources and Services Administration – COVID-19 [FAQs](#) for Maternal and Child Health Programs
- Health Resources and Services Administration – COVID-19 [FAQs](#) for [National Health Service Corps](#) and [Nurse Corps](#)
- Health Resources and Services Administration – COVID-19 [FAQs](#) for Ryan White HIV/AIDS Program
- HHS Office for Civil Rights – [Notice](#) of Enforcement Discretion for Telehealth
- HHS Office for Civil Rights – [FAQs](#) on HIPAA and Telehealth
- Office of the National Coordinator for Health Information Technology – Interoperability Standards [Advisory](#): Interoperability for COVID-19 Novel Coronavirus Pandemic
- Office of the National Coordinator for Health Information Technology – Interoperability [Proving Ground](#): COVID-19 Projects



- Substance Abuse and Mental Health Services Administration – Emergency [Grants](#) to Address Mental and Substance Use Disorders during COVID-19
- Substance Abuse and Mental Health Services Administration – COVID-19 [Information](#) for SAMHSA Discretionary Grant Recipients
- Substance Abuse and Mental Health Services Administration – COVID-19 Public Health Emergency Response and 42 CFR Part 2 [Guidance](#)
- Substance Abuse and Mental Health Services Administration – COVID-19: Interim [Considerations](#) for State Psychiatric Hospitals
- Substance Abuse and Mental Health Services Administration – Virtual Recovery [Resources](#)
- Substance Abuse and Mental Health Services Administration – Opioid Treatment Program [Guidance](#)
- Substance Abuse and Mental Health Services Administration – OTP [Guidance](#) for Patients Quarantined at Home with the Coronavirus
- Substance Abuse and Mental Health Services Administration – [FAQs](#): Provision of Methadone and Buprenorphine for the Treatment of Opioid Use Disorder in the COVID-19 Emergency